| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Repligen 136 | CTRPv2 | pan-cancer | AAC | 0.024 | 0.5 |
| mRNA | LRRK2-IN-1 | CTRPv2 | pan-cancer | AAC | 0.024 | 0.5 |
| mRNA | Sorafenib | FIMM | pan-cancer | AAC | -0.11 | 0.5 |
| mRNA | lenalidomide | GDSC1000 | pan-cancer | AAC | 0.024 | 0.5 |
| mRNA | HG-6-64-1 | GDSC1000 | pan-cancer | AAC | 0.022 | 0.5 |
| mRNA | KIN001-236 | GDSC1000 | pan-cancer | AAC | -0.022 | 0.5 |
| mRNA | tacedinaline | CTRPv2 | pan-cancer | AAC | -0.024 | 0.5 |
| mRNA | JQ-1:MK-0752 (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.021 | 0.5 |
| mRNA | AZD-2281 | FIMM | pan-cancer | AAC | -0.11 | 0.5 |
| mRNA | BRD-K80183349 | CTRPv2 | pan-cancer | AAC | -0.021 | 0.5 |